Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Beta Finch - Eli Lilly - LLY - EN cover art

Beta Finch - Eli Lilly - LLY - EN

Beta Finch - Eli Lilly - LLY - EN

Written by: Beta Finch
Listen for free

About this listen
AI-powered earnings call analysis for Eli Lilly (LLY). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch Economics Personal Finance
Episodes
  • Eli Lilly Q3 2026 Earnings Analysis
    Oct 29 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Eli Lilly's Q3 2026 results — and folks, this is a big one.

    **JORDAN:** Huge one. Stock popped over 6.5% on the news.

    **ALEX:** It really did. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Important stuff. Okay, Alex, let's talk numbers because they're staggering.

    **ALEX:** Revenue grew 39% year-over-year — that's nearly $7 billion in additional revenue in a single quarter. Non-GAAP EPS came in at $7.48, and gross margin actually expanded to 84.4%.

    **JORDAN:** And the guidance raise is what really got everyone's attention. Full-year revenue guidance moved up to $91-92 billion, and EPS guidance jumped to $35-36 — that's roughly a $4 per share increase at the midpoint from where they were tracking before.

    **ALEX:** Which is wild because this isn't the first raise this year. CFO Lucas Montarce basically said they've now raised full-year revenue guidance by about $10 billion since the start of 2026.

    **JORDAN:** And when analysts pushed on that — like, "are you guys just being too conservative?" — CEO David Ricks had a great answer. He basically said, look, we're in the middle of the largest category expansion in pharma history. There's real uncertainty here, and he'd rather beat estimates than miss them. Two big unknowns this year were the Medicare bridge program uptake and how deep international out-of-pocket demand would go — and both surprised to the upside.

    **ALEX:** Let's talk about that Medicare bridge program because it's honestly the story of the quarter. This opened up obesity medicine access to about 20 million seniors starting July 1st, and in just one quarter, over half a million people already filled a prescription.

    **JORDAN:** And Lilly is absolutely dominating that channel — 7 out of 10 new bridge patients are starting on a Lilly medicine. There was even a USC Schaeffer Center study cited saying this program could save Medicare over $20 billion cumulatively over ten years. That's a pretty powerful argument for why this program might get extended or made permanent.

    **ALEX:** Right, and that was actually a direct question in the Q&A — will this bridge program survive past 2026? Ricks sounded genuinely optimistic, citing strong uptake, appropriate use based on BMI and comorbidities, and that cost-effectiveness data. He thinks it could get folded into the permanent Part D benefit going forward.

    **JORDAN:** Let's not overlook the core business though — Mounjaro and Zepbound combined for over $16 billion in the quarter alone, contributing $6 billion of year-over-year growth. China was a standout too — Mounjaro became the first medicine there ever to cross $1 billion in its first full year, with 62% constant currency growth.

    **ALEX:** And it's not just incretins anymore. Management specifically called out that oncology, immunology, and neuroscience revenue combined actually doubled year-over-year. Jaypirca up 59%, Ebglyss up 59%, and Kisunla — their Alzheimer's drug — up a staggering 175%.

    **JORDAN:** That diversification story matters. David Ricks made a point of saying three-fourths of their clinical pipeline is actually outside of obesity. They don't want to be a one-trick pony, even though the trick is working extremely well right now.

    **ALEX:** Speaking of the pipeline, there was some really juicy data this quarter. Retatrutide — their triple agonist — went head-to-head with semaglutide in type 2 diabetics and basically more than doubled the weight loss, 20-21% versus 9.4%.

    **JORDAN:** And then there

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Eli Lilly Q2 2026 Earnings Analysis
    Aug 29 2026
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Eli Lilly's Q2 2026 results, and Jordan, I'll just say it up front — this was a big one.

    JORDAN: Big is an understatement. But before we get into the numbers, our standard reminder: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    ALEX: Right, with that said — let's talk numbers. Lilly's revenue grew 48% year-over-year in Q2. Their key products alone added almost $6.8 billion, and get this — oncology, immunology, and neuroscience combined grew 121% versus last year.

    JORDAN: That's a company firing on basically every cylinder. And the incretin franchise — Zepbound and Mounjaro — is still the engine room. Combined, those two brought in $14.9 billion in the quarter, contributing $6.3 billion of the total growth.

    ALEX: Gross margin ticked up to 86.3%, non-GAAP EPS came in at $8.38 — though that includes a $3.03 hit from acquired R&D charges, so the underlying number is even stronger. And naturally, they raised full-year guidance: revenue now expected between $85 and $87 billion.

    JORDAN: Which, by the way, is up $3 billion at the low end and $2 billion at the high end from prior guidance. That's not a small tweak — that's a company that's genuinely outperforming its own expectations.

    ALEX: Let's talk geography for a second, because the international story here is wild. China revenue grew 93% in constant currency. Rest of world — think Latin America, Asia — grew 136%. Lilly's international incretin market share is now around 55% globally.

    JORDAN: And this is the piece I think investors sometimes underweight — Mounjaro's global rollout is still in relatively early innings in a lot of these markets. Management basically said future growth outside the U.S. is going to come from market penetration, not just new country launches, since most of the big launch wave already happened last year.

    ALEX: Which actually ties into one of the more interesting analyst questions on the call — someone pushed back on guidance, basically asking "wait, doesn't this guide imply deceleration versus Q2?" And CFO Lucas Montarce had a pretty candid answer.

    JORDAN: Yeah, he pointed to a few real factors — there were some one-time favorable adjustments to rebate and discount estimates this quarter that won't repeat, last year's back half had a huge bolus of new-market Mounjaro launches that's now lapped, and there's normal seasonality — European summer holidays hit Q3, and diabetes has its own seasonal pattern in Q4. So it's less "conservative sandbagging" and more "the comp gets harder."

    ALEX: Fair enough. Now let's talk about the newer story here — Foundayo, their oral GLP-1. The U.S. launch has been a bit of a slow burn, but management said they're now seeing real inflection. Prescriber count went from 8,000 last quarter to 36,000 now, and the last week of July nearly doubled monthly volume.

    JORDAN: The Medicare GLP-1 Bridge Program is a big deal too — it launched July 1st and gives 20 million eligible Americans coverage for obesity GLP-1s at just $50 a month out-of-pocket. That's a 35% expansion in coverage overnight. Early signs are heavily skewed toward injectables — about 80% — but they're seeing real new-patient uptake on both fronts.

    ALEX: And internationally, the UAE numbers turned heads — $31 million in Foundayo sales in a single quarter, which is nearly half of total U.S. sales. One analyst flagged that as a signal of "explosive potential" once Foundayo rolls out more broadly, which management confirmed is coming mostly in 2027.

    JORDAN: On the pipeline side, retatrutide is the one to watch. Three positive Phase III trials — TRIUMPH-1, 2,

    This episode includes AI-generated content.
    Show More Show Less
    7 mins
  • Eli Lilly Q1 2026 Earnings Analysis
    Apr 30 2026
    # Beta Finch Podcast Script - Eli Lilly Q1 2026 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're diving into Eli Lilly's first quarter 2026 results - and wow, what a quarter this was. Jordan, before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Thanks Alex. And you're absolutely right about this being a wow quarter. Lilly just posted some absolutely staggering numbers. We're talking about 56% revenue growth year-over-year, bringing in what appears to be massive incretin revenues. But what really caught my attention was their guidance raise - they bumped up their full-year revenue expectations by $2 billion to between $82 and $85 billion.

    **ALEX:** That's incredible. Let me put that in perspective for our listeners - the midpoint of that guidance represents 28% growth for the full year. For a company of Lilly's size, that's just phenomenal. And the driving force here is clearly their GLP-1 portfolio - Mounjaro and Zepbound combined brought in $12.8 billion in global revenue just in Q1, contributing $6.7 billion of growth compared to last year.

    **JORDAN:** What's fascinating is how this growth is playing out globally. We saw really strong international momentum for Mounjaro. In markets like Brazil and Korea, they're claiming around 60% market share. And here's something interesting - they mentioned that generic semaglutide entry in some markets like India actually seems to be stimulating overall market growth rather than hurting Lilly's position.

    **ALEX:** That's a great point about the generics. CEO Dave Ricks made a really insightful comment during the Q&A about how this obesity market behaves differently from traditional pharma categories. He said that because so much of the business is out-of-pocket - 75% of ex-US Mounjaro business and a meaningful portion in the US - they see "quite expansionary volume" when they reduce prices. It's almost like the demand curve is more elastic than typical prescription drugs.

    **JORDAN:** Exactly. And speaking of new developments, let's talk about Koundeo - their newly approved oral GLP-1. This is huge because it's the first new incretin medicine launched with obesity as the primary indication, not diabetes. They mentioned having over 20,000 patients treated already with about 80% being new to the class entirely.

    **ALEX:** The Koundeo launch strategy is really interesting. They're taking a measured approach - they started with digital campaigns, moved to in-person physician promotion, and they're planning full-scale direct-to-consumer TV advertising in Q3. What I found telling was that they already have over 8,000 prescribers, with a third of them never having prescribed an oral GLP-1 before.

    **JORDAN:** And the access piece is critical. They've secured commercial access at two of the three largest pharmacy benefit managers, effective mid-May. Plus, the Medicare Bridge program extension through 2027 could be a game-changer - we're talking about $50 monthly copays for seniors. When an analyst asked about Medicare activation, management indicated this will be a gradual build through 2026 and into 2027.

    **ALEX:** Let's talk about their pipeline because they were incredibly busy on the R&D front. They announced four acquisitions this quarter - Orna Therapeutics for autoimmune CAR-T therapies, Centessa for sleep disorders, Colonia for cancer treatments, and Ajax for blood cancers. Plus they had positive Phase III data for multiple programs.

    **JORDAN:** The retatrutide data particularly caught my eye. This is their triple agonist - GIP, GLP-1, and glucagon. In the TRANSCEND T2D1 trial, patients lost an average of 25 to 37 pounds while also

    This episode includes AI-generated content.
    Show More Show Less
    8 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet